Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

294 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer.
Loupakis F, Biason P, Prete AA, Cremolini C, Pietrantonio F, Pella N, Dell'Aquila E, Sperti E, Zichi C, Intini R, Dadduzio V, Schirripa M, Bergamo F, Antoniotti C, Morano F, Cortiula F, De Maglio G, Rimassa L, Smiroldo V, Calvetti L, Aprile G, Salvatore L, Santini D, Munari G, Salmaso R, Guzzardo V, Mescoli C, Lonardi S, Rugge M, Zagonel V, Di Maio M, Fassan M. Loupakis F, et al. Among authors: rimassa l. Br J Cancer. 2019 Oct;121(7):593-599. doi: 10.1038/s41416-019-0560-0. Epub 2019 Sep 2. Br J Cancer. 2019. PMID: 31474758 Free PMC article.
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients.
Cappuzzo F, Varella-Garcia M, Finocchiaro G, Skokan M, Gajapathy S, Carnaghi C, Rimassa L, Rossi E, Ligorio C, Di Tommaso L, Holmes AJ, Toschi L, Tallini G, Destro A, Roncalli M, Santoro A, Jänne PA. Cappuzzo F, et al. Among authors: rimassa l. Br J Cancer. 2008 Jul 8;99(1):83-9. doi: 10.1038/sj.bjc.6604439. Epub 2008 Jun 24. Br J Cancer. 2008. PMID: 18577988 Free PMC article.
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma.
Santoro A, Pressiani T, Citterio G, Rossoni G, Donadoni G, Pozzi F, Rimassa L, Personeni N, Bozzarelli S, Rossoni G, Colombi S, De Braud FG, Caligaris-Cappio F, Lambiase A, Bordignon C. Santoro A, et al. Among authors: rimassa l. Br J Cancer. 2010 Sep 7;103(6):837-44. doi: 10.1038/sj.bjc.6605858. Epub 2010 Aug 17. Br J Cancer. 2010. PMID: 20717115 Free PMC article. Clinical Trial.
Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.
Di Bartolomeo M, Pietrantonio F, Perrone F, Dotti KF, Lampis A, Bertan C, Beretta E, Rimassa L, Carbone C, Biondani P, Passalacqua R, Pilotti S, Bajetta E; Italian Trials in Medical Oncology Group. Di Bartolomeo M, et al. Among authors: rimassa l. Target Oncol. 2014 Jun;9(2):155-62. doi: 10.1007/s11523-013-0283-8. Epub 2013 Jul 3. Target Oncol. 2014. PMID: 23821376 Clinical Trial.
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
Personeni N, Rimassa L, Verusio C, Barni S, Rubino L, Bozzarelli S, Villa E, Carnaghi C, Tronconi MC, Gerardi C, Galli F, Floriani I, Destro A, Raschioni C, Labianca R, Santoro A. Personeni N, et al. Among authors: rimassa l. Clin Colorectal Cancer. 2015 Sep;14(3):162-9. doi: 10.1016/j.clcc.2015.02.006. Epub 2015 Mar 6. Clin Colorectal Cancer. 2015. PMID: 25861836 Clinical Trial.
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer.
Pietrantonio F, Aprile G, Rimassa L, Franco P, Lonardi S, Cremolini C, Biondani P, Sbicego EL, Pasqualetti F, Tomasello G, Niger M, Casagrande M, Ghidini M, Muni R, Montrone S, Bergamo F, Berenato R, Fontanella C, Bozzarelli S, Moretto R, Battaglin F, Di Bartolomeo M, de Braud F, Miceli R. Pietrantonio F, et al. Among authors: rimassa l. Radiother Oncol. 2015 Nov;117(2):315-21. doi: 10.1016/j.radonc.2015.08.023. Epub 2015 Sep 4. Radiother Oncol. 2015. PMID: 26347495
KRAS mutation in lung metastases from colorectal cancer: prognostic implications.
Ghidini M, Personeni N, Bozzarelli S, Baretti M, Basso G, Bianchi P, Tronconi MC, Pressiani T, Grizzi F, Giordano L, Malesci A, Alloisio M, Laghi L, Santoro A, Rimassa L. Ghidini M, et al. Among authors: rimassa l. Cancer Med. 2016 Feb;5(2):256-64. doi: 10.1002/cam4.592. Epub 2015 Dec 29. Cancer Med. 2016. PMID: 26715198 Free PMC article.
Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.
Lonardi S, Sobrero A, Rosati G, Di Bartolomeo M, Ronzoni M, Aprile G, Massida B, Scartozzi M, Banzi M, Zampino MG, Pasini F, Marchetti P, Cantore M, Zaniboni A, Rimassa L, Ciuffreda L, Ferrari D, Barni S, Zagonel V, Maiello E, Rulli E, Labianca R; TOSCA (Three or Six Colon Adjuvant) Investigators. Lonardi S, et al. Among authors: rimassa l. Ann Oncol. 2016 Nov;27(11):2074-2081. doi: 10.1093/annonc/mdw404. Epub 2016 Aug 29. Ann Oncol. 2016. PMID: 27573560 Free article. Clinical Trial.
294 results